Diabetes, insuline treatment (Kela reimbursement)

KELA_DIAB_INSUL

No definition available.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

KELA reimbursements: KELA codes 103

42578

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

42578

diagram downward connector

Check minimum number of events None

42578

diagram downward connector

Include endpoints None

42578

diagram downward connector
KELA_DIAB_INSUL

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 41247 18631 22616
Unadjusted prevalence (%) 13.37 10.74 16.75
Mean age at first event (years) 54.14 53.18 54.94

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.02 1.93 [1.73, 2.16] 3.2e-32 4331
15 years 0.01 1.28 [1.17, 1.41] 3.7e-7 2245
5 years 0.00 1.54 [1.39, 1.72] 2.4e-15 780
1 year 0.00 2.40 [2.03, 2.85] 4.9e-24 216

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: KELA_DIAB_INSUL – Diabetes, insuline treatment (Kela reimbursement)
GWS hits: 87

Survival analyses between endpoints

Plot

before Diabetes, insuline treatment (Kela reimbursement)
after Diabetes, insuline treatment (Kela reimbursement)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Diabetes, insuline treatment (Kela reimbursement)